Thermo Fisher Scientific Option Alert: Jan 16 $490 Puts Sweep (15) near the Ask: 133 vs 109 OI; Earnings 4/23 Before Open [est] 

Thermo Fisher Scientific Option Alert: Jan 16 $490 Puts Sweep (15) near the Ask: 133 @ $40.9 vs 109 OI; Earnings 4/23 Before Open [est] Ref=$487.57

Thermo Fisher Scientific Bolsa (NYSE: TMO)

Thermo Fisher Scientific (NYSE:TMO) Bolsa

THERMO FISHER SCIENTIFIC INC

Thermo Fisher Scientific

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific Inc

TomTom NV

TOMOE ENGINEERING CO by Tomoe Engineering Co. Ltd.

Trimol Group Inc

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$50.00</td>
<td>$160.0K</td>
<td>4</td>
<td>2.0K</td>
</tr>
<tr>
<td>VRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$70.00</td>
<td>$55.4K</td>
<td>372</td>
<td>500</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$28.3K</td>
<td>6.7K</td>
<td>302</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$310.00</td>
<td>$25.5K</td>
<td>8.7K</td>
<td>173</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$40.00</td>
<td>$25.8K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$37.00</td>
<td>$47.8K</td>
<td>839</td>
<td>114</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$690.00</td>
<td>$37.0K</td>
<td>212</td>
<td>33</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$77.50</td>
<td>$36.0K</td>
<td>1.4K</td>
<td>26</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$470.00</td>
<td>$32.8K</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$680.00</td>
<td>$124.6K</td>
<td>10</td>
<td>11</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding IRON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on April 17, 2025. Parties traded 2000 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $160.0K, with a price of $80.0 per contract. There were 4 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold. 
• For VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we notice a call option sweep that happens to be bearish, expiring in 45 day(s) on May 16, 2025. This event was a transfer of 241 contract(s) at a $70.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $55.4K, with a price of $230.0 per contract. There were 372 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 290 day(s) on January 16, 2026. This event was a transfer of 59 contract(s) at a $25.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $480.0 per contract. There were 6708 open contracts at this strike prior to today, and today 302 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on April 17, 2025. Parties traded 37 contract(s) at a $310.00 strike. The total cost received by the writing party (or parties) was $25.5K, with a price of $690.0 per contract. There were 8768 open contracts at this strike prior to today, and today 173 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option sweep that happens to be bullish, expiring in 16 day(s) on April 17, 2025. This event was a transfer of 150 contract(s) at a $40.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $170.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, expiring in 108 day(s) on July 18, 2025. This event was a transfer of 90 contract(s) at a $37.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $47.8K, with a price of $532.0 per contract. There were 839 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bullish sentiment. It expires in 45 day(s) on May 16, 2025. Parties traded 30 contract(s) at a $690.00 strike. The total cost received by the writing party (or parties) was $37.0K, with a price of $1236.0 per contract. There were 212 open contracts at this strike prior to today, and today 33 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a put option trade with bearish sentiment. It expires in 290 day(s) on January 16, 2026. Parties traded 24 contract(s) at a $77.50 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $1500.0 per contract. There were 1454 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• For TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we notice a call option trade that happens to be bearish, expiring in 45 day(s) on May 16, 2025. This event was a transfer of 10 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $32.8K, with a price of $3280.0 per contract. There were 2 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
• Regarding MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we observe a call option trade with bearish sentiment. It expires in 654 day(s) on January 15, 2027. Parties traded 11 contract(s) at a $680.00 strike. The total cost received by the writing party (or parties) was $124.6K, with a price of $11330.0 per contract. There were 10 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKRO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IRON

MRNA

VRNA

10 Health Care Stocks With Whale Alerts In Today's Session

On Thursday, Solventum&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) hosted its 2025 Investor Day, during which it outlined its strategic priorities, its business segments, and its long-range plan (LRP) to drive <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">growth and value creation</a>.
Formerly&nbsp;3 M&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>)&nbsp;Health Care Business, Solventum, started trading as a newly independent healthcare <a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38018163/solventum-begins-trading-on-the-new-york-stock-exchange" rel="noreferrer noopener">company in April 2024</a>.
The company offers solutions for wound care, surgery, dental prevention, procedures, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44416081/solventum-to-present-value-creation-formula-and-long-range-plan-at-2025-investor-day" rel="noreferrer noopener">orthodontics, and software.</a>
&#8220;Solventum has tremendous potential, with attractive businesses, large and growing markets, and highly regarded brands. We have undertaken a significant transformation to unlock the potential of our Medical Surgical, Dental Solutions, and Health Information Systems businesses, positioning the company to drive accelerated growth and create shareholder value,&#8221; said&nbsp;Bryan Hanson, CEO of Solventum.
&#8220;Solventum has entered 2025 as a more focused company&#8230;Our long-range plan demonstrates the progress we made in the last year and reflects our confidence in our ability to accelerate sales growth, expand margins, deliver EPS growth, and improve free cash flow,&#8221; Hanson concluded.
Thermo Fisher Scientific Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)&nbsp;agreed to acquire Solventum&#8217;s Purification &amp; Filtration (P&amp;F) business for approximately <a target="_blank" href="https://www.benzinga.com/25/02/43940332/thermo-fisher-bets-big-on-bioproduction-with-solventums-unit-deal-worth-41-billion" rel="noreferrer noopener">$4.1 billion in cash in February</a>.
Solventum&#8217;s Purification &amp; Filtration business provides purification and filtration technologies for the production of biologics, medical technologies, and industrial applications.
Solventum reaffirmed its fiscal year 2025 guidance and announced its long-range plan (LRP) for 2025 through 2028:
<ul>
<li>Accelerate organic sales growth of 4% to 5% in 2028.</li>
<li>Expand operating margins to be 23% to 25% in 2028 (inclusive of ~200bps&nbsp;3M&nbsp;COGS increase).</li>
<li>Generate EPS&nbsp;CAGR of 10% over the 3 years ending 2028</li>
<li>Drive free cash flow conversion of 80%+</li>
</ul>
Solventum reported fourth-quarter adjusted EPS of $1.41, beating the consensus of $1.32, and sales of $2.07 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.05 billion</a>.
The company forecasts 2025 adjusted EPS of $5.45-$5.65, compared to a consensus of $5.50, and organic sales growth <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n44024720/solventum-reports-fourth-quarter-2024-financial-results-and-introduces-2025-full-year-guidance" rel="noreferrer noopener">of +1.0% to +2.0%</a>.
Price Action: SOLV stock is down 1.57% at $73.81 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44415440/accenture-q2-fy2025-earnings-almost-inline-with-expectations-new-bookings-fall-to-209-billion-tightens-annual-sales-growth-forecast" target="_blank" rel="noreferrer noopener">Accenture Q2 FY2025 Earnings Almost Inline With Expectations, New Bookings Fall To $20.9 Billion, Tightens Annual Sales Growth Forecast</a></li>
</ul>

Earnings

Large Cap

News

Guidance

Health Care

Movers

Trading Ideas

General

SOLV

3M Spin Off Solventum Targets Higher Margins, EPS Growth In 2025-2028 Strategy

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 20 years by 7.96% on an annualized basis producing an average annual return of 16.15%. Currently, Thermo Fisher Scientific has a market capitalization of $195.58 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 20 years ago, it would be worth $1,998.50 today based on a price of $518.41 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742415311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 20 years by 8.17% on an annualized basis producing an average annual return of 16.28%. Currently, Thermo Fisher Scientific has a market capitalization of $195.16 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 20 years ago, it would be worth $1,989.24 today based on a price of $517.32 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741961709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth This Much Today

Thermo Fisher Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) short percent of float has risen 7.84% since its last report. The company recently reported that it has 4.15 million shares sold short, which is 1.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Thermo Fisher Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741958126_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Thermo Fisher Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Thermo Fisher Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Thermo Fisher Scientific's peer group average for short interest as a percentage of float is 6.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on Thermo Fisher Scientific?

Whales with a lot of money to spend have taken a noticeably bullish stance on Thermo Fisher Scientific.
Looking at options history for Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations and 35% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $416,443 and 7, calls, for a total amount of $327,162.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $540.0 for Thermo Fisher Scientific, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Thermo Fisher Scientific stands at 76.5, with a total volume reaching 678.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Thermo Fisher Scientific, situated within the strike price corridor from $500.0 to $540.0, throughout the last 30 days.
<h3>Thermo Fisher Scientific 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741884346_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$57.8</td>
<td>$57.2</td>
<td>$57.03</td>
<td>$540.00</td>
<td>$193.2K</td>
<td align="right">189</td>
<td align="right">81</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$45.0</td>
<td>$43.4</td>
<td>$45.16</td>
<td>$540.00</td>
<td>$121.5K</td>
<td align="right">93</td>
<td align="right">81</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$56.9</td>
<td>$52.1</td>
<td>$52.1</td>
<td>$540.00</td>
<td>$46.8K</td>
<td align="right">5</td>
<td align="right">9</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/14/25</td>
<td>$20.0</td>
<td>$16.8</td>
<td>$18.5</td>
<td>$530.00</td>
<td>$46.2K</td>
<td align="right">73</td>
<td align="right">51</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$58.1</td>
<td>$56.9</td>
<td>$57.93</td>
<td>$540.00</td>
<td>$40.2K</td>
<td align="right">189</td>
<td align="right">137</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
In light of the recent options history for Thermo Fisher Scientific, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Thermo Fisher Scientific</h3>
<ul>
<li>Currently trading with a volume of 623,480, the TMO's price is down by -0.2%, now at $511.6. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 41 days.</li>
</ul>
<h3>Professional Analyst Ratings for Thermo Fisher Scientific</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $570.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Thermo Fisher Scientific, targeting a price of $570. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Thermo Fisher Scientific options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Markets

Market Whales and Their Recent Bets on TMO Options

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$35.00</td>
<td>$43.0K</td>
<td>680</td>
<td>1.7K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/14/25</td>
<td>$815.00</td>
<td>$26.5K</td>
<td>38</td>
<td>268</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$62.50</td>
<td>$125.9K</td>
<td>90</td>
<td>253</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$360.00</td>
<td>$119.2K</td>
<td>472</td>
<td>203</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$210.00</td>
<td>$95.5K</td>
<td>290</td>
<td>193</td>
</tr>
<tr>
<td>IQV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$180.00</td>
<td>$200.2K</td>
<td>31</td>
<td>111</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$490.00</td>
<td>$99.7K</td>
<td>92</td>
<td>77</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$165.00</td>
<td>$26.6K</td>
<td>6.1K</td>
<td>56</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$330.00</td>
<td>$80.8K</td>
<td>14</td>
<td>29</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$600.00</td>
<td>$101.9K</td>
<td>0</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 37 day(s) on April 17, 2025. This event was a transfer of 426 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $43.0K, with a price of $101.0 per contract. There were 680 open contracts at this strike prior to today, and today 1750 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be neutral, expiring in 3 day(s) on March 14, 2025. This event was a transfer of 20 contract(s) at a $815.00 strike. The total cost received by the writing party (or parties) was $26.5K, with a price of $1325.0 per contract. There were 38 open contracts at this strike prior to today, and today 268 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a put option sweep that happens to be bearish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 221 contract(s) at a $62.50 strike. This particular put needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $125.9K, with a price of $570.0 per contract. There were 90 open contracts at this strike prior to today, and today 253 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option trade that happens to be bearish, expiring in 10 day(s) on March 21, 2025. This event was a transfer of 200 contract(s) at a $360.00 strike. The total cost received by the writing party (or parties) was $119.2K, with a price of $596.0 per contract. There were 472 open contracts at this strike prior to today, and today 203 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a put option sweep that happens to be bullish, expiring in 31 day(s) on April 11, 2025. This event was a transfer of 193 contract(s) at a $210.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $95.5K, with a price of $495.0 per contract. There were 290 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding IQV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), we observe a put option sweep with bullish sentiment. It expires in 283 day(s) on December 19, 2025. Parties traded 110 contract(s) at a $180.00 strike. This particular put needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $200.2K, with a price of $1820.0 per contract. There were 31 open contracts at this strike prior to today, and today 111 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bullish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 23 contract(s) at a $490.00 strike. The total cost received by the writing party (or parties) was $99.7K, with a price of $4335.0 per contract. There were 92 open contracts at this strike prior to today, and today 77 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a call option trade with bullish sentiment. It expires in 101 day(s) on June 20, 2025. Parties traded 35 contract(s) at a $165.00 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $760.0 per contract. There were 6139 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $330.00 strike. The total cost received by the writing party (or parties) was $80.8K, with a price of $3110.0 per contract. There were 14 open contracts at this strike prior to today, and today 29 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with neutral sentiment. It expires in 464 day(s) on June 18, 2026. Parties traded 10 contract(s) at a $600.00 strike. The total cost received by the writing party (or parties) was $101.9K, with a price of $10193.0 per contract. There were 0 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

VKTX

10 Health Care Stocks Whale Activity In Today's Session

David Kostin, the Chief U.S. Equity Strategist of Goldman Sachs, has revised his earnings growth forecast, citing a weaker economic outlook, and highlighted a shift in market trends.
What Happened: On CNBC&#8217;s &#8216;Squawk on the Street&#8217;, Kostin discussed his revised earnings growth forecast and market trends. Initially projected at 11%, the earnings growth forecast for 2025 has now been adjusted to 9%. 
Despite this, Kostin maintains that the earnings growth for 2026 remains at 7%, unchanged. He also stated that the S&amp;P 500 year-end target remains at 6500, suggesting an 11% gain from current levels.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Goldman Sachs&#039; Kostin: We&#039;re revising EPS growth forecast lower, but healthcare poses opportunity" width="500" height="281" src="https://www.youtube.com/embed/Pn9ySR9ygao?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Kostin also noted a shift in investment strategy, with investors moving from &#8220;excitement&#8221; (cyclicals) to &#8220;boredom&#8221;&nbsp;(defensive stocks) amid tariff&nbsp;uncertainties. He identified healthcare and consumer staples as preferred sectors for their stability and less sensitivity to the ongoing trade war. He also named&nbsp;Thermo Fisher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) and Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) as strong investment options. 
Furthermore, he notes a shift in focus from AI infrastructure and hyperscalers to software companies that would be leveraging AI to amplify their revenues, for instance, MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>). 
According to Kostin, uncertainty around tariffs makes forecasting difficult, but models suggest&nbsp;earnings will be impacted through unit volumes and margins. The strategist estimated that a 5% increase in tariffs&nbsp;could reduce earnings growth by&nbsp;1-2%.
SEE ALSO: <a href="https://www.benzinga.com/general/space/25/03/44102170/spacex-scraps-starship-flight-test-on-monday-too-many-question-marks-about-this-flight-says-ceo-elon-musk">SpaceX Scraps Starship Flight Test On Monday: &#8216;Too Many Question Marks About This Flight&#8230;,&#8217; Says CEO Elon Musk</a>
Why It Matters: This shift in investment strategy is noteworthy, considering that institutional investors were bullish on technology and financials during the fourth quarter of 2024. Investors were seen <a href="https://www.benzinga.com/markets/equities/25/02/43878703/institutional-investors-load-up-on-technology-and-financial-stocks-in-q4-while-reducing-positions-in-healthcare-sector-amid-political-uncertainty">pulling back</a> from the healthcare sector, which Kostin now identifies as a preferred sector. Even Warren Buffet&#8216;s Berkshire Hathaway trimmed its stake in healthcare provider DaVita Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), bringing down the ownership to 45%.
These market shifts and Kostin&#8217;s revised forecast underline the uncertainties in the current economic climate but also highlight potential&nbsp;opportunities in defensive sectors and&nbsp;AI-driven businesses. That being said, Kostin expects the falling bond yields to offset some tariff effects, potentially benefiting the economy. He summed up by saying that GDP growth is the primary driver of earnings, with interest rates and inflation playing secondary roles.
The S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) climbed 1.12% to close at 5,842.63 on Wednesday after President Donald Trump pushed back auto tariffs on Canada and Mexico by one month.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/25/03/44159766/us-indicts-12-chinese-nationals-over-alleged-global-hacking-operation-targeting-critics-been-paying-hackers-for-hire-to-inflict-digital-harm-on-americans">US Indicts 12 Chinese Nationals Over Alleged Global Hacking Operation Targeting Critics: &#8216;&#8230;Been Paying Hackers-For-Hire To Inflict Digital Harm On Americans&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Goldman Sachs Cuts Earnings Growth Outlook, Sees Investors Move From 'Excitement' To 'Boredom'

Citigroup analyst Patrick Donnelly maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Neutral and lowers the price target from $650 to $570.

Price Target

Analyst Ratings

Citigroup Maintains Neutral on Thermo Fisher Scientific, Lowers Price Target to $570

&quot;Trian commends Solventum on the announced sale of its Purification &amp; Filtration business and believes this is an important first step in the Company&#39;s value creation journey. We believe that part of what attracted strategic interest at such a high valuation multiple was the division&#39;s differentiated technology and material science &ndash; attributes inherited from 3M which are present at Solventum&#39;s remaining businesses, and which we believe remain underappreciated by the market today.&quot;
&nbsp;
Thermo Fisher Also Commented &quot;Excluding Financing Costs, the Transaction Is Expected to Be Accretive by $0.28 in That Period. This Reflects the Very Strong Day One Cost Synergies When Solventum&#39;s Allocated Segment Costs Are Replaced by Lower Run Rate Costs Within Thermo Fisher.&quot;
&nbsp;
&nbsp;

Trian Fund Management Which Beneficially Owns ~5% Of Solventum Corporation Comments On Solventum's Recently Announced Sale Of Its Purification & Filtration Business To Thermo Fisher Scientific

Dan&nbsp;Loeb‘s&nbsp;Third Point LLC, which has a varied mix of stock from across the sectors, did some major portfolio restructuring in the <a target="_blank" href="https://www.benzinga.com/topic/dan-loeb" rel="noreferrer noopener">last quarter of 2024</a>.
According to recent 13F filings,&nbsp;reflecting his holding as of Dec. 31, 2024, Loeb slashed a stake in the major Life Sciences Tools &amp; Services company Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514625001713/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">to </a>1,900,000 from 1,950,000 shares <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624005927/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">in </a>the third quarter of 2024, a decline of around 2.5%.
Notably, the investor has been cutting stake in Danaher in the last couple of quarters. Earlier, he held 2,050,000 shares <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624004004/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">as </a>of second quarter of 2024 and 2,450,000 shares as <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514623004511/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">of </a>third quarter of 2023.
Instead, the investor acquired a stake in Danaher&#8217;s major peer Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), attaining 350,000 shares in the fourth quarter 2024.
Read: <a target="_blank" href="https://www.benzinga.com/25/02/43861240/repligens-q4-earnings-beat-2025-guidance-highlights-market-growth" rel="noreferrer noopener">Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook</a>
DHR Major Events:
<ul>
<li>In January, the company reported weaker-than-expected fourth-quarter earnings, with adjusted earnings per share of $2.14 missing the street view of $2.16 and sales of $6.54 billion (+2%), beating the analyst <a href="https://www.benzinga.com/news/earnings/25/01/43298036/danaher-q4-eps-miss-expectations-amid-diagnostics-segment-lag" target="_blank" rel="noreferrer noopener">consensus estimate of $6.42 billion</a>.</li>
<li>Danaher expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter. However, it anticipates a 3% year-over-year increase in <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">core revenue for the full year of 2025</a>.</li>
<li>Following the earnings release, several analysts cut the price forecast on the stock, with Barclays analyst Luke Sergott lowering the price forecast from $275 to $240 and Wells Fargo analyst Brandon Couillard curtailing the price target from $280 to $240 and <a href="https://www.benzinga.com/25/01/43336758/danaher-analysts-cut-their-forecasts-after-downbeat-earnings" target="_blank" rel="noreferrer noopener">both maintaining an Equal-Weight</a>.</li>
<li>This month, Danaher raised quarterly dividend <a href="https://www.benzinga.com//node/43866316" target="_blank" rel="noreferrer noopener">per share from&nbsp;$0.27&nbsp;to&nbsp;$0.32</a>.</li>
</ul>
TMO Major Events:
<ul>
<li>Last month, the company reported fourth-quarter adjusted earnings per share of $6.10, beating the street view of $5.94 and sales of $11.395 billion (+5% year over year) outpaced the analyst <a href="https://www.benzinga.com/25/01/43337781/thermo-fisher-q4-earnings-beat-estimates-margin-expands" target="_blank" rel="noreferrer noopener">consensus estimate of $11.277 billion</a>.</li>
<li>Following the earnings release, several analysts raised the price forecast on the stock, with Morgan Stanley analyst Tejas Savant increasing the price target from&nbsp;$647&nbsp;to&nbsp;$678 and Wells Fargo analyst Brandon Couillard upped <a href="https://www.benzinga.com/quote/TMO/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast from&nbsp;$660&nbsp;to&nbsp;$680</a>.</li>
<li>This month, Thermo Fisher Scientific raised its quarterly dividend<a href="https://www.benzinga.com//node/43830343" target="_blank" rel="noreferrer noopener"> from $0.39 to $0.43 per share</a>.</li>
<li>Thermo Fisher inked a 10-year VPPA with X-ELIO to enhance renewable energy access in pharmaceutical and healthcare supply chains through the Lorca solar project, set to launch <a href="https://www.benzinga.com/pressreleases/25/02/b43460138/thermo-fisher-scientific-accelerates-100-percent-renewable-electricity-goal-for-european-operation" target="_blank" rel="noreferrer noopener">in early 2026 with three industry partners</a>.</li>
</ul>
Year to date, Danaher shares declined around 10% while Thermo Fisher rose 0.66%, both underperforming the iShares U.S. Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>), which gained about 5%&nbsp;over the same time frame.
Also, the companies top peers Agilent Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) fell roughly 0.3% and IQVIA Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) declined about 1.3% so far this year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43796723/dan-loebs-third-point-boosts-meta-holdings-now-a-top-4-position" target="_blank" rel="noreferrer noopener">Dan Loeb&#8217;s Third Point Boosts Meta Holdings, Now A Top 4 Position</a></li>
</ul>
Photo: Shutterstock

ETFs

iShares Trust Dow Jones US Healthcare Sector Index Fund

Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor

On Tuesday, Thermo Fisher Scientific Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) agreed to acquire Solventum&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) Purification &amp; Filtration business for approximately $4.1 billion in cash.
Solventum&#8217;s Purification &amp; Filtration business provides purification and filtration technologies for the production of biologics, medical technologies and industrial applications.
The Solventum business operates globally, with sites in the Americas, Europe, the Middle East, Africa and the Asia-Pacific region. The company has approximately 2,500 employees.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43337781/thermo-fisher-q4-earnings-beat-estimates-margin-expands" rel="noreferrer noopener">Thermo Fisher Q4 Earnings Beat Estimates, Margin Expands</a>
In 2024, Solventum&#8217;s Purification &amp; Filtration business generated approximately $1 billion in revenue.
Solventum&#8217;s Purification &amp; Filtration business complements Thermo Fisher&#8217;s bioproduction business.
&#8220;The addition of Solventum&#8217;s business is an outstanding strategic fit with our company and will create significant value for our customers and shareholders,&#8221; said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher.
The transaction is expected to be completed by the end of 2025.
The Purification &amp; Filtration business will become part of Thermo Fisher&#8217;s Life Sciences Solutions segment and is expected to generate mid-to-high-single-digit organic growth. The application of the PPI Business System will enable strong margin expansion and meaningful synergy realization.
The transaction is expected to be dilutive to adjusted EPS&nbsp;by $0.06 in the first year of ownership.
Excluding financing costs, the transaction is expected to be accretive by $0.28 in that period.
Thermo Fisher expects to realize approximately $125 million of adjusted operating income from revenue and cost synergies by year five following the close.
Price Action: TMO stock closed at $535.55 on Monday. SOLV stock is up 1.93% at $77.75 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43938612/eli-lilly-expands-zepbound-vial-options-lowers-prices-for-25-mg-5-mg-doses" target="_blank" rel="noreferrer noopener">Eli Lilly Expands Zepbound Vial Options, Lowers Prices For 2.5 mg, 5 Mg Doses</a></li>
</ul>
Photo: Shutterstock

Thermo Fisher Bets Big On Bioproduction With Solventum's Unit Deal Worth $4.1 Billion

Thermo Fisher To Acquire Solventum's Purification And Filtration Business For $4.1B In Cash

<a href="https://www.wsj.com/business/deals/thermo-fisher-nears-deal-for-solventum-filtration-unit-e0bb5519?mod=Searchresults_pos2&amp;page=1" title="https://www.wsj.com/business/deals/thermo-fisher-nears-deal-for-solventum-filtration-unit-e0bb5519?mod=Searchresults_pos2&amp;page=1">https://www.wsj.com/business/deals/thermo-fisher-nears-deal-for-solventum-filtration-unit-e0bb5519?mod=Searchresults_pos2&amp;page=1</a>

Wall Street Journal Reported Monday, Thermo Fisher Scientific Nears Deal For Solventum's Purification And Filtration Business; Deal Could Be Announced This Week

Investors with a lot of money to spend have taken a bullish stance on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with TMO, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Thermo Fisher Scientific.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 12%, bearish.
Out of all of the options we uncovered, 7 are puts, for a total amount of $317,353, and there was 1 call, for a total amount of $35,057.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $500.0 to $610.0 for Thermo Fisher Scientific over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Thermo Fisher Scientific options trades today is 223.5 with a total volume of 322.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Thermo Fisher Scientific's big money trades within a strike price range of $500.0 to $610.0 over the last 30 days.
<h3>Thermo Fisher Scientific Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740168995_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$24.5</td>
<td>$22.8</td>
<td>$24.5</td>
<td>$560.00</td>
<td>$66.1K</td>
<td align="right">504</td>
<td align="right">17</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$25.8</td>
<td>$23.1</td>
<td>$24.6</td>
<td>$560.00</td>
<td>$51.6K</td>
<td align="right">504</td>
<td align="right">83</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$43.3</td>
<td>$38.9</td>
<td>$40.61</td>
<td>$530.00</td>
<td>$44.6K</td>
<td align="right">2</td>
<td align="right">11</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$25.8</td>
<td>$23.1</td>
<td>$24.6</td>
<td>$560.00</td>
<td>$44.2K</td>
<td align="right">504</td>
<td align="right">101</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$13.1</td>
<td>$12.3</td>
<td>$12.3</td>
<td>$500.00</td>
<td>$40.5K</td>
<td align="right">388</td>
<td align="right">37</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
<h3>Present Market Standing of Thermo Fisher Scientific</h3>
<ul>
<li>With a trading volume of 788,069, the price of TMO is down by -0.81%, reaching $533.5.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 61 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Thermo Fisher Scientific</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $672.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Thermo Fisher Scientific, which currently sits at a price target of $715. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Thermo Fisher Scientific, targeting a price of $650. 
&#x2A; An analyst from Raymond James downgraded its action to Outperform with a price target of $667. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Thermo Fisher Scientific with a target price of $680. 
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on Thermo Fisher Scientific, which currently sits at a price target of $650. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Thermo Fisher Scientific options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Thermo Fisher Scientific Unusual Options Activity

Thermo Fisher Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) short percent of float has risen 13.19% since its last report. The company recently reported that it has 3.95 million shares sold short, which is 1.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Thermo Fisher Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740084326_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Thermo Fisher Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Thermo Fisher Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Thermo Fisher Scientific's peer group average for short interest as a percentage of float is 5.56%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Thermo Fisher Scientific's Recent Short Interest

CNBC Final Trades: XOM, LNG, TMO

Dividends

Thermo Fisher Scientific Increases Quarterly Dividend From $0.39 To $0.43

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 15 years by 5.16% on an annualized basis producing an average annual return of 17.2%. Currently, Thermo Fisher Scientific has a market capitalization of $200.16 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 15 years ago, it would be worth $1,053.53 today based on a price of $523.29 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739910608_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 15 Years

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 10 years by 5.75% on an annualized basis producing an average annual return of 16.83%. Currently, Thermo Fisher Scientific has a market capitalization of $226.56 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 10 years ago, it would be worth $4,800.04 today based on a price of $592.33 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738595709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Press Releases

Thermo Fisher Scientific Accelerates 100 Percent Renewable Electricity Goal for European Operations with New Solar Power Agreement with X-ELIO

GeminiBio Appoints Mike Stella to Board

Thermo Fisher Scientific Elects New Director to Board

Thermo Fisher Scientific Increases Quarterly Dividend

Thermo Fisher Scientific to Present at TD Cowen 45th Annual Health Care Conference on March 3, 2025

Thermo Fisher Scientific to Acquire Solventum's Purification and Filtration Business

Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

Trian Comments on Solventum's Sale of its Purification & Filtration Business

Thermo Fisher Scientific Introduces the Vulcan™ Automated Lab to Transform Semiconductor Analysis

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 23, 2025

AMGN

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Illumina

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Citigroup

Scotiabank

Raymond James

Wells Fargo

Screenshot 2024-12-19 at 7.13.05 PM

Biotech

MYNZ

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Comments

Thermo Fisher Scientific

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL